TrialBMJ open2018

OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.

Feng Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.